Orthocell Ltd. engages in the business of developing and commercializing biological medical devices and cell therapies. The company is headquartered in Perth, Western Australia. The company went IPO on 2014-08-12. The firm is focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Its portfolio of products includes Striate+, Remplir, and OrthoACI. Striate+ is a sterile, resorbable collagen membrane used for guided bone and tissue regeneration in dental applications. Remplir is a collagen scaffold used in peripheral nerve repair. OrthoACI or autologous chondrocyte implantation is used for the treatment of articular cartilage defects in the knee and ankle. OrthoACI uses the patient’s own healthy cartilage cells called chondrocytes to assist the regeneration of damaged cartilage. The firm is engaged in the development of its tendon cell therapy in the United States. Its autologous tendon therapy is an advanced injectable cellular therapy for the treatment of chronic tendon injuries.
Follow-Up Questions
What is the price performance of ORHHF stock?
The current price of ORHHF is $0, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Orthocell Ltd?
Orthocell Ltd belongs to Biotechnology industry and the sector is Health Care
What is Orthocell Ltd market cap?
Orthocell Ltd's current market cap is $0
Is Orthocell Ltd a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Orthocell Ltd, including 1 strong buy, 3 buy, 1 hold, 0 sell, and 1 strong sell
